Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Slides:



Advertisements
Similar presentations
Computational methods for genomics-guided immunotherapy
Advertisements

Computational methods for genomics-guided immunotherapy Sahar Al Seesi Computer Science & Engineering Department, UCONN Immunology Department, UCONN Health.
Immuno and Epigenetic Therapies Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520.
Copyright © 1999 American Medical Association. All rights reserved.
Socializing Individualized T-Cell Cancer Immunotherapy
Cell Mediated Immunity
Computational methods for genomics-guided immunotherapy
Adaptive Immune Response (Cell Mediated Immunity)
TCR-MHC-peptide(s): in vivo veritas
Supplementary figure 1. Gating strategy used for FACS sorting of TIL subsets (CD3+, CD3+CD8+/-, CD3+CD8+PD-1+/-). Two representative fresh tumor samples.
Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency.
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.
Sahar Al Seesi University of Connecticut CANGS 2017
T cell mediated immunity
by Mohini Rajasagi, Sachet A. Shukla, Edward F. Fritsch, Derin B
Engineering regulatory T cells against factor VIII inhibitors
T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Tumor Evolution: A Problem of Histocompatibility
Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer  Takahiro Karasaki, MD, Kazuhiro Nagayama,
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Applications of Immunogenomics to Cancer
Intrinsic and acquired trastuzumab resistance.
Somatic promoters correlate with immunoediting signatures.
Copy-number alterations in an archival breast cancer sample.
Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells by Martin R. Müller,
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Figure 2 Logistical requirements for autologous
Neoantigen-specific TCR expansion in stimulated T-cell cultures.
Mechanism of CTLA-4-induced immunosuppression.
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
Cell Mediated Immunity
Fig. 1 Cancer exome–based identification of neoantigens.
Neoantigen analysis on patient CTE-0013 who achieved clinical benefit
Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment
Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing by Aishwarya Iyer, Dylan Hennessey,
Human cells produce type I and III IFNs upon Af stimulation.
Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.
Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;
Fig. 2 Estimate of the neoantigen repertoire in human cancer.
Natural processing and presentation of the HOM-MEL-40/SSX2-derived p peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.
Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.
Leukemic blasts express a “hypoxia signature
Direct recognition of MHC II/TARP14-27 on tumor cells by HTL
Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.
HLA-DR53–restricted HTL responses to peptide TARP1-14.
ADNs are largely distinct from CDNs
Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.
Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.
Inactivation of human TRAC and CD52 genes by TALENs
PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.
Patient Tregs express normal levels of suppression.
Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.
Ten most frequent TCRs in the bulk 12TILs comprise >99% of the TIL population, and the neoantigens are shown to be the most dominant clones. Ten most frequent.
Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.
Validation of NAA's cancer specificity in lung cancer.
Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.
Strategies for personalized precision immunotherapy.
Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.
Defining the eTME genes.
Fig. 1 Cancer exome–based identification of neoantigens.
Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.
HLA restriction of spCD4 T-cell responses.
Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.
Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.
BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.
PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.
Varying the MHC-I affinity, TCR affinity or antigen dose alters the phenotype of CD8 T cells ex vivo. Varying the MHC-I affinity, TCR affinity or antigen.
Percentages of peripheral blood CD4 and CD8 T cells expressing the activation markers HLA-DR and CD25 in the atopic asthmatics (AA), atopic controls (AC),
Presentation transcript:

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Whole-exome sequencing was performed on the pretreatment and postprogression tumor and matched normal samples. Exome data were applied in a neoantigen prediction pipeline that evaluates antigen processing, MHC binding, and gene expression to generate neoantigens specific to the patient's HLA haplotype. Truncal neoantigens were identified by correcting for tumor purity and ploidy, and the TCR repertoire was evaluated at baseline, at the time of response, and upon emergence of resistance. Putative eliminated neoantigens at the time of resistance were used to generate peptides and stimulate autologous T cells, followed by TCR next-generation sequencing. PBL, peripheral blood lymphocyte. Valsamo Anagnostou et al. Cancer Discov 2017;7:264-276 ©2017 by American Association for Cancer Research